Sir, Quinolones are recognized as one of the most widely prescribed classes of antibiotics used to treat infections caused by Gramnegative and Gram-positive bacteria. 1 In humans, quinolones are used to treat infections of the urogenital, respiratory and gastroinestinal tracts as well as a range of anatomically diverse infections in swine, poultry, cattle and companion animals and in aquaculture. 2 In the environment, fluoroquinolones break down slowly (half-life of 100 days) and it is possible to measure trace levels of the drug in exposed environments. 3 The environmental impact of quinolones, particularly fluoroquinolones from humans, agriculture and pharmaceutical production facilities, is a cause of concern as residues and metabolic breakdown products released from the body of target species provides a selection pressure that impacts the ecology of non-target bacterial, invertebrate and vertebrate populations, where it can influence natural mutation rates and lateral gene transfer. 2 The cellular targets of quinolones are bacterial type II topoisomerases, including DNA gyrase and topoisomerase IV. 4 DNA gyrase functions in the management of DNA supercoiling and topological stress, while topoisomerase IV has a role in unlinking replicated daughter chromosomes. 4 The genes encoding QnrA, QnrB, QnrC, QnrD, QnrS and QnrVC are found on the chromosome or on plasmids and confer resistance to quinolones and low-level resistance to fluoroquinolones. The Qnr proteins belong to the pentapeptide repeat family and function to protect DNA gyrase and topoisomerase IV, enabling bacteria to resist the actions of quinolones. QnrA is 218 amino acids in length and seven alleles have been described (qnrA1-7). The closest homologues of qnrA genes in clinically important Enterobacteriaceae are found in Shewanella algae, 6 Gram-negative bacilli that live in diverse and unique aquatic environments. 7 Five alleles of qnrA (qnrA2-5 and qnrA7) have been identified in S. algae, 6, 8, 9 prompting suggestions that qnrA genes were transferred from S. algae into the Enterobacteriaceae. 10, 11 Here, we report the identification of a novel, chromosomally encoded qnrA allele, qnrA8 (GenBank accession number KY554783), isolated from environmental S. algae strains SA1 and SA2 from the Georges River, Sydney, in 2011.
The qnrA8 nucleotide sequence differs from the qnrA1 sequence by 24 nucleotides ( Figure S1 , available as Supplementary data at JAC Online). The majority of the polymorphisms encode silent mutations; however, G 
156
D was novel to this allele ( Figure 1a ). Personal correspondence with George Jacoby saw the sequence receive the unique designation of qnrA8.
12 BLASTN analysis using the qnrA8 nucleotide sequence from strain SA1 as the query identified a qnr allele in Klebsiella pneumoniae plasmid IncA/C-LS6 (GenBank NC_021667.1) to be the closest homologue. 13 A Mauve alignment shows that the region within the K. pneumoniae plasmid IncA/C-LS6 flanking the qnrA6 allele is similar to the region flanking qnrA8 in SA1 and SA2 (Figure 1b ). These observations are consistent with the hypothesis that qnrA alleles found on mobile genetic elements in the Enterobacteriaceae circulating in clinical environments have been captured from environmental S. algae.
14 Further, our analyses indicate that ISCR1 has played a role in capturing qnr genes, positioning them in close proximity to 3 0 -CS of clinical class 1 integrons. 15 The IS10 does not appear to be associated with the capture of the qnrA allele and is likely to have been acquired independently.
The antimicrobial susceptibility of S. algae SA1 and SA2 were tested against 31 antibiotics using the Vitek 2 Compact System (Version 05.04 at Concord Hospital, Sydney) following the bioMérieux guidelines and the calibrated dichotomous sensitivity test (CDS) as outlined in the CDS manual. 16 Notably, SA1 and SA2 were susceptible to nalidixic acid (30 lg), ciprofloxacin (2.5 lg) and norfloxacin (2 lg). This observation is not without precedent as the susceptibility of S. algae to quinolones and fluoroquinolones carrying qnrA genes has been noted. 8 In S. algae, qnrA2 is expressed in response to cold shock (temperatures ,20 C) and not with DNA-damaging agents, such as fluoroquinolones, 9 while in Escherichia coli qnrA6 promotes bacterial fitness in the absence of antibiotics. 17 A link between bacterial supercoiling, to which DNA gyrase is vital, and thermotolerance and thermoresistance has been described. 18 Collectively these data suggest the qnr genes may have evolved to regulate DNA supercoiling in response to fluctuations in temperature, a role that would be advantageous as an evolutionary adaptation to seasonal changes in temperature in the environment that Shewanella spp. inhabits.
In summary, a novel, chromosomally encoded qnrA allele, qnrA8, was identified in environmental S. algae strains SA1 and SA2 from Sydney, Australia. The immediate genetic environment that flanks the qnrA8 gene in the Shewanella strains is remarkably similar to the plasmid-encoded qnrA genes found in multipleantibiotic-resistant Enterobacteriaceae, providing further support for the notion that these genes may have been sourced from aquatic Shewanella spp. qnrA8 did not confer resistance to quinolones or fluoroquinolones in strains SA1 and SA2, but the gene may function to enhance bacterial fitness.
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It provides low-level resistance that by itself does not exceed the clinical breakpoint for susceptibility, but nonetheless facilitates selection of higher-level resistance during treatment and makes infection harder to treat. 4 We have recently used MALDI-TOF MS to detect the AAC(6 0 )-Ib-cr enzyme in Enterobacteriaceae by visual inspection of the mass spectra of the acetylation reaction that yields an increase of 43 Da in the mass of the fluoroquinolones ciprofloxacin and norfloxacin. 5 The aim of this study was to automate data analysis and establish a simplified and reliable detection algorithm that enables quantification of the acetylation in relation to enzyme activity.
In a preliminary step to establish the cut-off for positivity, we tested a collection of 81 previously studied isogenic Escherichia coli control strains (all derived from E. coli ATCC 25922) carrying combinations of four chromosomally mediated quinolone resistance mechanisms (including modifications in gyrA and parC or marR deletion), plasmid-mediated qnr and AAC(6 0 )-Ib-cr enzyme, or the plasmid-mediated qepA2 efflux pump (Table S1 , available as Supplementary data at JAC Online). 5 Of the 81 isolates, 10 were AAC(6 0 )-Ib-cr producers. In the second part of the study, we evaluated the optimized quantitative approach in a series of 122 blinded clinical isolates (one per patient and epidemiologically unrelated) obtained in January 2017 from hospitalized patients (Complejo Hospitalario Universitario A Coruña) with urinary tract infections. Isolates were selected from among E. coli and Klebsiella pneumoniae phenotypically expressing an ESBL. 3 The isolates were further characterized in relation to the presence of the AAC(6 0 )-Ib-cr enzyme. 6 The MALDI-TOF MS acetylation reaction assay was performed as described by Oviaño et al. 5 To establish the working concentration, the isogenic E. coli control strains were submitted to evaluation with ciprofloxacin and norfloxacin concentrations of 0.25 and 0.50 mg/mL.
The presence of the AAC(6 0 )-Ib-cr enzyme was determined by automated analysis of the spectra performed with an in-house program, MALDI Biotyper PeakShift Prototype (Bruker Daltonik GmbH), written in the freely available software package R. 7, 8 The spectra were first baseline subtracted and normalized to the maximum peak. Automated peak selection was performed and peaks belonging to the corresponding antibiotic drug and the respective acetylation products were labelled, with a tolerance of 0. 5 Mass peaks were selected with a resolution .300 and a signal-to-noise threshold of 4. The AUC was determined for each spectrum. The relative acetylation or the logIQ (logarithm intensity quantification) was then calculated as the ratio of the AUCs, by using the formula logIQ " log (sum [AUC acetylated peak intensities ])/(sum [AUC non-acetylated peak intensities ]). The a-cyano-4-hydroxycinnamic acid peak at 379.02 Da was used for calibration, with a tolerance of 1 Da. A cut-off value for the logIQ value for determining the activity of the AAC(6 0 )-Ib-cr enzyme was established for both ciprofloxacin and norfloxacin. The blinded clinical isolates were analysed under the conditions previously optimized for the isogenic control strains and data evaluation was performed using the MALDI Biotyper PeakShift Prototype.
Clear separation of the isogenic E. coli controls strains into two groups was achieved for both ciprofloxacin and norfloxacin acetylation reactions when using 0.2 mg/mL. A mean logIQ value of ,#1.5 was obtained for all isolates not carrying the AAC(6 0 )-Ib-cr 
